A mouse homolog to the avian sarcoma virus src protein is a member of a protein kinase cascade

Cell
|July 1, 1981
PubMed

Insights

A new protein kinase, PKF, has been identified in Ehrlich ascites tumor cells, acting within a cascade that impacts Na+K+-ATPase activity and aerobic glycolysis. PKF is homologous to the src gene product, pp60src.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • A cascade of membrane-bound protein kinases (PKL, PKS, PKM) exists in Ehrlich ascites tumor cells.
  • This cascade is active only in tumor tissue, unlike in mouse brain.
  • The cascade's activation leads to the phosphorylation of the Na+K+-ATPase beta subunit.

Purpose of the Study:

  • To purify and characterize a fourth protein kinase, PKF, involved in this cascade.
  • To elucidate the role of PKF in the kinase cascade and its relationship to pp60src.
  • To understand how the cascade activation contributes to the high aerobic glycolysis in tumor cells.

Main Methods:

  • Purification of protein kinase F (PKF).
  • Characterization of PKF's phosphorylation activity and its position within the kinase cascade.
  • Comparison of PKF with the src gene product (pp60src) using antiserum precipitation, substrate phosphorylation assays, tryptic mapping, and binding studies.

Main Results:

  • PKF phosphorylates PKL, activating it, and is phosphorylated by PKS, placing it within the cascade.
  • PKF is homologous to pp60src, sharing similar substrate specificities (PKL, vinculin) and structural characteristics.
  • Activation of the cascade, including PKF, results in inefficient Na+ pumping due to Na+K+-ATPase beta subunit phosphorylation, contributing to aerobic glycolysis.

Conclusions:

  • PKF is a crucial component of the tumor-specific protein kinase cascade.
  • PKF's homology to pp60src suggests a conserved mechanism in viral oncogenesis and tumor cell metabolism.
  • The identified kinase cascade and its effect on Na+K+-ATPase activity offer insights into the metabolic reprogramming of cancer cells.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...